0
By clicking the button, I accept the Terms of Use of the service and its Privacy Policy, as well as consent to the processing of personal data.
Don’t have an account? Signup
Powered by :
The production of India's first indigenously developed quadrivalent Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer, by the Serum Institute of India will start in the first quarter of 2023 which got delayed due to Covid-19 pandemic, said SII CEO Adar Poonawala on Friday.
Share this article
If you liked this article share it with your friends.they will thank you later